Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3

Alessandra Mangia, Franco Bandiera, Giuseppe Montalto, Leonardo Mottola, Valeria Piazzolla, Nicola Minerva, Adriano Pellicelli, Giovanni L. Ricci, Marina Cela, Vito Carretta, Gaetano Scotto, Donato Bacca, Brigida Annicchiarico, Mario Romano, Maurizio Russello, Giorgio Barbarini, Ernesto Agostinacchio, Angelo Andriulli

Research output: Contribution to journalArticle

Abstract

Background & Aims: The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established. Methods: Four hundred and fourteen patients received Peg-interferon alpha-2b plus 1000-1200 mg of ribavirin daily according with body weight > or

Original languageEnglish
Pages (from-to)1000-1005
Number of pages6
JournalJournal of Hepatology
Volume53
Issue number6
DOIs
Publication statusPublished - Dec 2010

Keywords

  • HCV genotype 3
  • Peg-interferon
  • Ribavirin
  • Short treatment

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3'. Together they form a unique fingerprint.

  • Cite this

    Mangia, A., Bandiera, F., Montalto, G., Mottola, L., Piazzolla, V., Minerva, N., Pellicelli, A., Ricci, G. L., Cela, M., Carretta, V., Scotto, G., Bacca, D., Annicchiarico, B., Romano, M., Russello, M., Barbarini, G., Agostinacchio, E., & Andriulli, A. (2010). Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. Journal of Hepatology, 53(6), 1000-1005. https://doi.org/10.1016/j.jhep.2010.04.042